Home / Business and Economy / Indian Pharma's Mega Deal: Sun Pharma Acquires Organon
Indian Pharma's Mega Deal: Sun Pharma Acquires Organon
27 Apr
Summary
- Sun Pharma's Organon acquisition is India's largest pharma overseas deal.
- This deal ranks second among all Indian outbound acquisitions.
- Tata Steel's Corus Group acquisition in 2007 remains the largest.
Sun Pharmaceutical Industries Ltd. has announced a significant move, proposing to acquire US-based Organon & Co for an enterprise value of ₹11.75 billion. This transaction marks a historic moment, becoming the largest overseas acquisition ever undertaken by an Indian pharmaceutical company. The deal's magnitude also places it as the second-largest outbound acquisition by an Indian entity overall. This distinction is currently held by Tata Steel's 2007 acquisition of Corus Group Plc for $12 billion. Other notable Indian outbound deals include Bharti Airtel's $10.7 billion acquisition of Zain Telecom's African operations and Hindalco Industries' $6 billion purchase of Novelis in 2007. Looking ahead, Tata Motors is set to acquire Iveco Group's commercial vehicle business for an estimated $4.5 billion in 2025, representing its largest buyout.
